These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 16202486)

  • 1. A novel synthetic adjuvant effectively enhances the immunogenicity of the influenza vaccine.
    Segura-Velázquez R; Pérez-Torres A; Rosas G; Toledo A; Restelli M; Acosta E; Corral R; Rosetti F; Fragoso G; Grinstein S; Sciutto E
    Vaccine; 2006 Feb; 24(8):1073-80. PubMed ID: 16202486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection.
    Bungener L; Geeraedts F; Ter Veer W; Medema J; Wilschut J; Huckriede A
    Vaccine; 2008 May; 26(19):2350-9. PubMed ID: 18400340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The novel adjuvant IC31 strongly improves influenza vaccine-specific cellular and humoral immune responses in young adult and aged mice.
    Riedl K; Riedl R; von Gabain A; Nagy E; Lingnau K
    Vaccine; 2008 Jun; 26(27-28):3461-8. PubMed ID: 18495302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influenza vaccine: development of a novel intranasal and subcutaneous recombinant adjuvant.
    Segura-Velázquez R; Cervantes J; Acosta E; Sánchez-Betancourt I; Villalobos N; Rodarte LF; Restelli M; Fragoso G; Sciutto E
    Vaccine; 2013 Aug; 31(37):4009-16. PubMed ID: 23746458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice.
    Joseph A; Itskovitz-Cooper N; Samira S; Flasterstein O; Eliyahu H; Simberg D; Goldwaser I; Barenholz Y; Kedar E
    Vaccine; 2006 May; 24(18):3990-4006. PubMed ID: 16516356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants.
    Radosević K; Rodriguez A; Mintardjo R; Tax D; Bengtsson KL; Thompson C; Zambon M; Weverling GJ; Uytdehaag F; Goudsmit J
    Vaccine; 2008 Jul; 26(29-30):3640-6. PubMed ID: 18514980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bordetella pertussis monophosphoryl lipid A as adjuvant for inactivated split virion influenza vaccine in mice.
    Quintilio W; Kubrusly FS; Iourtov D; Miyaki C; Sakauchi MA; Lúcio F; Dias Sde C; Takata CS; Miyaji EN; Higashi HG; Leite LC; Raw I
    Vaccine; 2009 Jun; 27(31):4219-24. PubMed ID: 19393709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel emulsion adjuvant increases the immunogenic responses and protective efficacy of an inactivated influenza vaccine in BALB/c mice.
    Wang S; Ke CW; Zou LR; Jing Z; Xie GX; Li X
    Intervirology; 2009; 52(5):252-7. PubMed ID: 19622895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral adjuvant activity for nasal influenza vaccines caused by combination of two trihydroxy fatty acid stereoisomers from the tuber of Pinellia ternata.
    Nagai T; Shimizu Y; Shirahata T; Sunazuka T; Kiyohara H; Omura S; Yamada H
    Int Immunopharmacol; 2010 Jun; 10(6):655-61. PubMed ID: 20230917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective effect of nasal immunization of influenza virus hemagglutinin with recombinant cholera toxin B subunit as a mucosal adjuvant in mice.
    Isaka M; Zhao Y; Nobusawa E; Nakajima S; Nakajima K; Yasuda Y; Matsui H; Hasegawa T; Maeyama J; Morokuma K; Ohkuma K; Tochikubo K
    Microbiol Immunol; 2008 Feb; 52(2):55-63. PubMed ID: 18380802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterosubtypic protection conferred by combined vaccination with M2e peptide and split influenza vaccine.
    Wu F; Yuan XY; Huang WS; Chen YH
    Vaccine; 2009 Oct; 27(43):6095-101. PubMed ID: 19056447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incorporation of LpxL1, a detoxified lipopolysaccharide adjuvant, in influenza H5N1 virosomes increases vaccine immunogenicity.
    de Vries JJ; Bungener L; Ter Veer W; van Alphen L; van der Ley P; Wilschut J; Huckriede A
    Vaccine; 2009 Feb; 27(6):947-55. PubMed ID: 19059296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza.
    Pushko P; Tumpey TM; Van Hoeven N; Belser JA; Robinson R; Nathan M; Smith G; Wright DC; Bright RA
    Vaccine; 2007 May; 25(21):4283-90. PubMed ID: 17403562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The humoral immune response and protective efficacy of vaccination with inactivated split and whole influenza virus vaccines in BALB/c mice.
    Cox RJ; Hovden AO; Brokstad KA; Szyszko E; Madhun AS; Haaheim LR
    Vaccine; 2006 Nov; 24(44-46):6585-7. PubMed ID: 16839650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model.
    Ninomiya A; Imai M; Tashiro M; Odagiri T
    Vaccine; 2007 May; 25(18):3554-60. PubMed ID: 17293015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long- and short-time immunological memory in different strains of mice given nasally an adjuvant-combined nasal influenza vaccine.
    Asanuma H; Fujihashi K; Miyakoshi T; Yoshikawa T; Fujita-Yamaguchi Y; Kojima N; Nakata M; Suzuki Y; Tamura S; Kurata T; Sata T
    Vaccine; 2007 Sep; 25(39-40):6975-80. PubMed ID: 17716790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced protective immunity against H5N1 influenza virus challenge by vaccination with DNA expressing a chimeric hemagglutinin in combination with an MHC class I-restricted epitope of nucleoprotein in mice.
    Tao P; Luo M; Pan R; Ling D; Zhou S; Tien P; Pan Z
    Antiviral Res; 2009 Mar; 81(3):253-60. PubMed ID: 19135483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two doses of parenterally administered split influenza virus vaccine elicited high serum IgG concentrations which effectively limited viral shedding upon challenge in mice.
    Hovden AO; Cox RJ; Madhun A; Haaheim LR
    Scand J Immunol; 2005 Oct; 62(4):342-52. PubMed ID: 16253121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model.
    Hagenaars N; Mastrobattista E; Glansbeek H; Heldens J; van den Bosch H; Schijns V; Betbeder D; Vromans H; Jiskoot W
    Vaccine; 2008 Dec; 26(51):6555-63. PubMed ID: 18848856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.